[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-decline\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-decline":34},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,97,0,25,[9,66,91,124,162,200,234,278,308,333,357,386,424,455,480,504,531,555,580,626,654,680,710,733,762],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":35,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100651071","the-basic-s-feasibility-study-for-vascular-risk-reduction-100651071",false,"NCT07755631","The BASIC-S Feasibility Study for Vascular Risk Reduction","Piloting an Integrated Lifestyle Intervention for Vascular Risk Reduction: The BASIC-S Feasibility Study","BASIC-S","Inclusion Criteria:\n\n* Adults aged 18 years and older currently employed at or recently retired from the London Health Sciences Centre (LHSC) or Western University (with an operational focus on pre-retirees aged 50 years and older).\n* The primary applicant (not their partner, if applicable) must be within two years before or after their retirement date.\n* Spouse or cohabitating partner of an enrolled primary participant. Cohabitating partners may include a common-law partner, adult child, close friend, or roommate who lives with the primary participant and shares common health goals. Enrollment of partners is optional but strongly encouraged.\n* Capable of providing informed consent.\n* Has access to a mobile device capable of receiving Short Message Service (SMS) communications and viewing PDF documents.\n* Physically able to safely engage in light-to-moderate intensity physical activity.\n\nExclusion Criteria:\n\n* Medical conditions that preclude safe participation in physical activity (for instance, unstable angina, uncontrolled arrhythmia, severe heart failure) without physician clearance.\n* Active or unstable psychiatric illness, defined as hospitalization for psychiatric care within the preceding 6 months or modifications to antipsychotic or mood-stabilizing pharmacotherapy within the preceding 3 months. Participants with stable, medically managed psychiatric conditions remain eligible.\n* Severe cognitive impairment that compromises the ability to provide informed consent or independently use study-related technology.\n* Inability to read and understand English sufficiently to provide informed consent and complete study procedures.",true,"ALL","18 Years",{"count":22,"type":23},120,"ESTIMATED","INTERVENTIONAL",[26],"NA","Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging. To address this, we developed the BASIC-S framework, targeting Blood pressure, Activity, Sleep, Interaction (socially), Consumption (nutrition), and Support using partner support and motivational interviewing. This individual-focused approach bypasses the logistical and financial barriers of complex clinical interventions by using sustained behavioral science to support gradual lifestyle changes. This study is a single-center, mixed-methods, cluster-randomized pilot trial evaluating the feasibility of the BASIC-S protocol in an occupational setting. A maximum of 60 households (120 participants) will be randomized 1:1 to either the BASIC-S intervention (motivational coaching, secure video check-ins, automated text messages, and a digital workbook) or standard care. Outcomes will assess feasibility, acceptability, and the validity of new tracking metrics to inform a future full-scale trial.",[29,30,31,32,33,34],"Hypertension (HTN)","Vascular Diseases","Stroke","Dementia","Cardiovascular Risk Factor","Cognitive Decline",[36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Lifestyle Intervention","Motivational Interviewing","Primary Prevention","Behavioral Medicine","Brain Health","Cognition","Mental Health","Social Activity","Social Isolation","Physical Activity","Blood Pressure","Activity","Sleep","Interaction","Consumption","Support","Partnering","NOT_YET_RECRUITING","2026-08-18",{"date":56,"type":57},"2026-08-19","ACTUAL",{"date":59,"type":23},"2026-10-01",{"date":61,"type":23},"2027-10-01",{"name":63,"class":64},"Andrew Appleton","OTHER",1,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":19,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":24,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":65},"100587800","optimizing-cns-dha-delivery-in-elderly-adults-at-risk-for-dementia-100587800","NCT06933095","Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia","Inclusion Criteria:\n\n1. men and women 55 to 82 years old;\n2. presence of subjective cognitive decline or mild cognitive decline using the SCD questionnaire, DEX, EMQ, MoCA; and mCDR;\n3. No contraindication to a lumbar puncture (LP) unless opting to not have the LP (e.g., thrombocytopenia, coagulopathy, concomitant use of anticoagulant medications, etc.);\n4. fluency in English;\n5. ability to comprehend and comply with the research protocol; and\n6. provision of written informed consent.\n\nExclusion Criteria:\n\n1. diagnosis of dementia due to AD, Parkinson's disease, frontotemporal dementia, multi-infarct dementia, head trauma with loss of consciousness lasting more than 5 minutes and resulting in persisting functional decline within the three years prior to enrollment, epilepsy, leukoencephalopathy, other neurological conditions that would interfere the study objectives, mMIST \\\u003C8 or MoCA-MI score \\\u003C7;\n2. self-reported history of any psychotic disorder or bipolar disorder;\n3. diagnosis of atrial fibrillation, pancreatic, liver, kidney or hematological coagulation disorder;\n4. allergy to shellfish or seafood;\n5. current substance use causing physiological dependence or persisting change in functional capability;\n6. concomitant, regular use of medications that might affect primary outcome measures or adversely interact with the study product including anticoagulant medications;\n7. weekly fish consumption more than 1 x 3 oz servings and\u002For use of DHA-containing supplements within 3 months prior to screening.","55 Years","82 Years",{"count":75,"type":23},153,[26],"The purpose of this placebo-controlled trial is to compare the effects of 24-weeks supplementation with LPC-DHA and TAG-DHA on cerebrospinal fluid and blood DHA levels, as well as biomarkers of central neurodegenerative and neurotrophic activity, in elderly adults experiencing early signs of cognitive\u002Fmemory decline including those with mild cognitive impairment (MCI). Extant evidence supports our overarching hypothesis that LPC-DHA supplementation will be more effective than TAG-DHA for increasing central (CSF) DHA levels and improving biomarker profiles in elderly adults. To assess this hypothesis, the following aims are proposed:\n\nSPECIFIC AIM 1: To compare the effects of LPC-DHA and TAG-DHA supplementation on peripheral and CSF DHA levels in elderly adults experiencing early signs of cognitive\u002Fmemory decline.\n\nSPECIFIC AIM 2: To compare the effects of LPC-DHA and TAG-DHA supplementation on neurotrophic and neurodegenerative biomarkers.\n\nSecondary Aim: To investigate whether changes in CSF DHA levels correlate with changes in objective measures of executive functioning and episodic memory performance.",[79,34,80,81],"Eldery People","Memory Decline","DHA CNS Delivery","RECRUITING","2026-08-17",{"date":56,"type":57},{"date":86,"type":57},"2024-09-15",{"date":88,"type":23},"2029-09-15",{"name":90,"class":64},"University of Cincinnati",{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":101,"conditions":102,"keywords":110,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":65},"100440369","cognitive-impairment-in-colorectal-cancer-patients-receiving-cytotoxic-chemotherapy-100440369","NCT05014399","Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy","Chemo Brain","Inclusion Criteria:\n\n* Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) prior to study-specific screening procedures. Must be able to provide study-specific informed consent prior to study entry.\n* A histologically-confirmed colorectal tumor\n* Patients who will be treated with cytotoxic chemotherapies including Capecitabine, Oxaliplatin, 5 fluorouracil, and Irinotecan are eligible.\n* Patients must not have received cytotoxic chemotherapy previous to enrollment.\n\nExclusion Criteria:\n\n* Prior administration of anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents\n* Patients having mental incompetence as assessed by study PI, which would hinder completion of the surveys\n* Pregnant or breastfeeding\n* Any known brain metastases\n* Non-English speaking patients\n* Patients who have been diagnosed with any neuro-cognitive disorder including traumatic brain injuries, Alzheimer's disease, Parkinson's disease, Huntington's disease, and Creutzfeldt-Jakob disease.\n* Patients deemed inappropriate to participate in this study by the study PI or coordinator will be excluded.",{"count":99,"type":23},60,"OBSERVATIONAL","The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.",[103,104,105,106,107,108,109,34],"Neoplasm, Colorectal","Cognitive Impairment","Cognitive Dysfunction","Cognitive Change","Chemo-brain","Chemo Fog","Chemotherapy Effect",[111,112,113,114,104,96],"Palliative Care","Palliative Oncology","Supportive Care","Supportive Oncology","2026-08-13",{"date":117,"type":57},"2026-08-14",{"date":119,"type":57},"2021-09-20",{"date":121,"type":23},"2031-10",{"name":123,"class":64},"Joseph McCollom",{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":19,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":24,"phases":134,"briefSummary":135,"conditions":136,"keywords":141,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100649253","prevalence-of-mild-cognitive-impairment-and-dementia-in-patients-admitted-to-non-neurological-rehabilitation-wards-100649253","NCT07731334","Prevalence of Mild Cognitive Impairment and Dementia in Patients Admitted to Non-neurological Rehabilitation Wards","COGinREHAB","Inclusion Criteria:\n\n* Age ≥45 years\n* Hospitalization for at least 7-10 days for a non-neurological condition, in cardiac, pulmonary, or orthopedic intensive rehabilitation units, or intermediate care units\n* Adequate fluency in the Italian language\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Illiteracy\n* Severe, uncorrected visual impairment and\u002For hearing loss\n* Severe verbal communication deficit\n* Inability to remain seated for the duration of the assessment\n* Inability to use the dominant upper limb\n* Altered state of consciousness or alertness (e.g., delirium)\n* Severe scalp skin lesions or dermatitis precluding electrode application for neurophysiological recordings\n* Previous or current history of severe psychiatric disorders (e.g., psychotic disorders, bipolar disorder, severe major depressive disorder with psychotic symptoms, current suicidal risk, or other psychiatric conditions judged by the investigator to interfere with study participation, procedural compliance, or interpretation of results)\n* Previous history or current presence of clinically relevant neurological pathologies other than cognitive impairment (e.g., epilepsy, stroke, neurodegenerative diseases such as Parkinson's disease or multiple sclerosis, moderate-to-severe traumatic brain injury, brain tumors, central nervous system infections, or other neurological conditions that may influence cognitive, behavioral, or neurological functioning, or otherwise compromise the study objectives)","45 Years",{"count":133,"type":23},384,[26],"Cognitive impairment is common among older adults hospitalized for non-neurological conditions but often goes unrecognized, particularly in rehabilitation settings where clinical attention is mainly focused on physical recovery. The COGinREHAB study is a multicenter, prospective, longitudinal interventional study conducted at three rehabilitation centers of the Fondazione Don Carlo Gnocchi in Italy (Florence and Milan).\n\nThe study will enroll 384 patients aged 45 years or older who are hospitalized for at least 7-10 days in cardiac, pulmonary, or orthopedic intensive rehabilitation units, or in intermediate care units, for conditions unrelated to the nervous system.\n\nAt admission, all participants undergo a clinical and cognitive screening visit. Patients whose screening results suggest possible cognitive impairment then undergo a more extensive neuropsychological evaluation. In those with confirmed cognitive impairment, additional blood tests are performed to measure biomarkers of neurodegeneration (GFAP, neurofilament light chain, and phosphorylated tau-217), together with APOE genotyping and a non-contrast brain CT scan. In a subset of these patients, resting-state EEG, auditory event-related potentials, actigraphy, and overnight polysomnography are also performed. Patients with confirmed cognitive impairment are invited to a follow-up visit 12 months later to assess whether their cognitive profiles and biological markers have changed.\n\nThe main purpose of the study is to estimate how frequently cognitive impairment occurs among patients admitted to non-neurological rehabilitation units, including how often it was previously undiagnosed. The study will also describe the clinical, biological, and neurophysiological profile of these patients and examine how cognitive impairment evolves over one year.",[137,138,139,140,34],"MCI","Mild Cognitive Impairment (MCI)","Mild Cognitive Impairment","Cognitive Deficit",[139,142,143,144,32,145,146,147,148,149,150,151],"Cognitive Screening","Multimodal Assessment","Cognitive Trajectories","Non-Neurological Rehabilitation","Plasma Biomarkers","Neurodegeneration","Neurophysiological Measures","Longitudinal Study","APOE Genotype","MoCA","2026-08-05",{"date":154,"type":57},"2026-08-10",{"date":156,"type":57},"2026-01-20",{"date":158,"type":23},"2028-12",{"name":160,"class":64},"Fondazione Don Carlo Gnocchi ETS",3,{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":19,"minAge":72,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":24,"phases":173,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":199},"100515198","the-effects-of-successful-osa-treatment-on-memory-and-ad-biomarkers-in-older-adults-study-100515198","NCT05988385","The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study","The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults (ESSENTIAL) Study","ESSENTIAL","Inclusion Criteria:\n\n* Cognitively normal (TiCS ≥29)\n* Age 55-85 years\n* Moderate - severe OSA defined as AHI4 ≥20 events\u002Fhour or AHI3A\\>40\u002Fhr using a hypopnea criterion of a 4% oxygen desaturation (AHI4) or 3% oxygen desaturation and\u002For EEG arousal (AHI3A), or equivalent based on in-home testing - Testing must have been completed in past 12 months or confirmed by repeat test\n* Not currently on therapy for OSA and has not received treatment for OSA for at least 6months\n* Able and willing to be treated for OSA (Treatment group)\n* Fluency in English or Spanish\n\nExclusion Criteria:\n\n* Documented diagnosis of chronic insomnia, or sleep onset insomnia based on Insomnia Severity Index - an answer of severe or very severe in the screening form\n* Documented diagnosis of circadian rhythm disorder\n* Any current use of supplemental oxygen\n* Other sleep-related breathing disorders (central sleep apnea, etc) based on AASM criteria\n* Current shift work involving night shift (regular work between 12am and 6am or night shift) within the past 6 mo\n* Anticipated scheduled bariatric surgery within the next 3 months\n* Chronic regular (\\> 2 nights per week) of cannabis for sleep\n* Chronic regular use (\\> 2 nights per week) of sedatives\u002Fhypnotics for sleep\n* Diagnosis of uncontrolled psychiatric disease in the last six months , and\u002For history of schizophrenia or bipolar disorder. Controlled conditions will include major depressive disorder, panic disorder, generalized anxiety disorder, OCD, substance use disorders, and alcohol abuse\u002Fdependence. Personality disorders and neurodevelopmental disorders (e.g. autism, ADHD) are allowed if cognition is within normal limits.\n* Taking methylphenidate for ADHD. Unless on stable dose which will be reviewed by the PI to determine.\n* Taking GLP-1 agonist semaglutide (Ozempic, Wegovy, Rybelsus), or tirzepatide (Mounjaro, Zepbound), or similar for weightloss, and planning to lose an additional 20lbs or more at the time of enrollment. PI Discretion for determination of why they are taking the drug based on conversation with subject and medical chart, will be documented in form of Note-to-file in the subject's records\n* Presence of other comorbid condition that would lead to inability to complete the study protocol (including follow-up for 2 years), or that would affect cognition (e.g. clinically relevant endocrine or hematological conditions).\n* Does not have a regular sleeping environment (i.e., sleeps in a different setting \\> 2 nights per week).\n* Currently pregnant or planning to become pregnant.\n* Prior diagnosis of a Central nervous system (CNS) disease, such as multiple sclerosis, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, a loss of consciousness \\> 24 hours, or traumatic brain injury as identified by the Cumulative Illness Rating Scale for Geriatrics (CIRS). Participants who are diagnosed with MCI or Alzheimer's disease based on neuropsychological testing will be excluded. Delirium in the last 12 months.\n* Near-miss or prior automobile accident \"due to sleepiness\" within the past 12 months.\n* Employed as a commercial driver during the study (for example, bus drivers, train engineers, airplane pilots).\n* Any use of neuroleptics, benzodiazepines, barbiturates, opiates or anti-amyloid therapies.\n* Use of other cognitive enhancing drugs will also be excluded if initiated in the last 3 months, or not on stable dose.\n* Consumption of \\>14 alcohol drinks per week, unless alcohol consumption can be reduced if initiated in the last 3 months.","85 Years",{"count":172,"type":23},200,[26],"The Effects of Successful OSA TreatmENT on Memory and AD BIomarkers in Older AduLts (ESSENTIAL) study is a 5-year, multicenter randomized open-label trial that will screen 400 cognitively normal older adults recruited from well-established sleep clinics at 4 academic medical centers, with newly diagnosed moderate-severe OSA. An expected 200 OSA patients will be then randomized to one of two groups: i) a 3-month OSA treatment by any combination of PAP, OAT, and positional therapy that results in an \"effective\" AHI4%\\\u003C 10\u002Fhour and AHI3A\\\u003C20\u002Fhour (see below); ii) a waitlist control group to receive treatment at the conclusion of the 3-month intervention period. Both groups will continue follow-up for 24 months on stable therapy to determine if sustained improvements in sleep are associated with improvement in cognitive function and AD biomarkers.",[176,34],"Obstructive Sleep Apnea",[176,178,179,180,181,182,183,184,185,186,187,188,189],"OSA","Cognitive decline","Alzheimer Disease","AD","AD biomarkers","Positive Airway Pressure","PAP","CPAP","Oral appliance therapy","OAT","Positional therapy","Sleep-dependent memory","2026-08-04",{"date":192,"type":57},"2026-08-06",{"date":194,"type":57},"2024-08-29",{"date":196,"type":23},"2028-05-31",{"name":198,"class":64},"California Pacific Medical Center Research Institute",4,{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":19,"minAge":208,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":24,"phases":211,"briefSummary":212,"conditions":213,"keywords":216,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":233},"100649116","vivifrail-exercise-program-in-nonagenarians-effects-on-function-muscle-and-cognition-100649116","NCT07731529","Vivifrail Exercise Program in Nonagenarians: Effects on Function, Muscle, and Cognition","Effects of a Multicomponent Exercise Program Based on the Vivifrail Protocol on Functional Capacity, Muscle Morphology, and Cognition in Nonagenarians: A Randomized Clinical Trial","Vivifrail","Inclusion Criteria:\n\n* Aged 90 years or older\n* Living in the community (own or family home)\n* Able to walk independently or with a walking aid (cane or walker), without third-party assistance\n* Minimum cognitive capacity to understand and perform the exercises (MMSE, education-adjusted cutoffs)\n* Adequate home conditions to perform the program\n* Availability of a family member or caregiver to support the sessions\n* Signed informed consent (with legal guardian assistance when needed)\n\nExclusion Criteria:\n\n* \\- Total inability to walk or permanent bedridden condition\n* Severe cognitive impairment preventing safe understanding and execution of exercises\n* Severe orthopedic, neurological, or rheumatological conditions preventing exercise\n* Concurrent participation in another structured exercise program\n* Anticipated unavailability (relocation, planned hospitalization, or institutionalization) during the intervention\n* Refusal to sign informed consent or absence of a legal guardian when required","90 Years",{"count":210,"type":23},54,[26],"This randomized clinical trial investigates the effects of a home-based multicomponent exercise program (Vivifrail) on physical function, muscle morphology, and cognition in community-dwelling adults aged 90 years and older. Participants are randomized into three groups: Vivifrail at least twice a week, Vivifrail at least three times a week, or a control group. Outcomes are assessed at baseline, 12 weeks, and 24 weeks. The primary outcome is physical function measured by the Short Physical Performance Battery (SPPB).",[214,215,34],"Frailty","Aging",[206,217,218,219,220,221,222,223],"Multicomponent exercise","Nonagenarians","Physical function","Short Physical Performance Battery","Muscle quality","Muscle morphology","Home-based exercise","2026-07-24",{"date":226,"type":57},"2026-07-28",{"date":228,"type":23},"2026-07",{"date":230,"type":23},"2027-09",{"name":232,"class":64},"Federal University of Rio Grande do Sul",2,{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":18,"sex":19,"minAge":131,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":24,"phases":245,"briefSummary":246,"conditions":247,"keywords":256,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":65},"100625406","long-term-effects-of-walnut-consumption-on-brain-function-100625406","NCT07422220","Long-Term Effects of Walnut Consumption on Brain Function","Long-Term Effects of Walnut Consumption on Brain Function in Men and Women With Abdominal Obesity","WalBrain","Inclusion Criteria:\n\n* Men and women, aged between 45-75 years\n* Women postmenopausal: two or more years after last menstruation\n* Waist circumference of ≥102 cm for men and ≥88 cm for women (abdominal obesity)\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study\n* No difficult venipuncture as evidenced during the screening visit\n\nExclusion Criteria:\n\n* Allergy or intolerance to walnuts\n* Left-handedness (effects on brain function differ between left- and right-handed adults)\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Diabetic patients\n* Familial hypercholesterolemia\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use of products or dietary supplements (e.g., dietary fiber or antioxidant dietary supplements (vitamin C and E), fish or seaweed oil capsules) known to interfere with the main outcomes as judged by the principal investigators\n* Use of medication to treat blood pressure, lipid, or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident\n* Contra-indications for MRI imaging (e.g., pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)","75 Years",{"count":244,"type":23},55,[26],"Rationale: Healthy foods, including mixed nuts, may improve brain function, which is essential for cognitive and metabolic health, and may contribute to improved food intake regulation. It is therefore important to investigate the specific effects of walnuts on cerebral blood flow responses before and after intranasal insulin administration, as well as their associated functional benefits. The investigators hypothesize that long-term walnut consumption improves vascular function and insulin-sensitivity in the brain, thereby enhancing cognitive performance and appetite control in abdominally obese men and women. Objective: The primary objectives are to investigate in abdominally obese adults the effects of 24-week walnut consumption on (regional) vascular function and insulin-sensitivity in the brain, while the investigators will also assess changes in cognitive performance and appetite-related brain reward activity (secondary objectives). Cerebral blood flow responses before (brain vascular function) and after the administration of intranasal insulin spray (brain insulin-sensitivity) will be quantified by the non-invasive gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labeling (ASL). Study design: This intervention study will have a randomized, controlled parallel design. The total study duration will be 24 weeks. Study population: Fifty-five abdominally obese men and (postmenopausal) women (aged 45-75 years) without a history of cardiovascular diseases or complaints will participate. This study population is expected to have a decreased cerebral blood flow at baseline and are also at increased risk of cognitive impairment, allowing for improvement by the intervention. Intervention: Study participants will receive daily 50 g (about 15% of energy) of raw walnuts (walnut intervention) or no walnuts (control intervention) for 24 weeks. Main study parameters\u002Fendpoints: At baseline and after 24 weeks (follow-up), participants will visit the research facilities for assessments. The primary endpoint is the difference in the cerebral blood flow response before and after intranasal insulin administration between the walnut and control intervention. Cognitive performance will be assessed, while the investigators will also focus on appetite-related brain reward activity (secondary outcomes).",[248,249,250,251,252,253,254,255,34],"Healthy","Brain Insulin Sensitivity","Cerebral Blood Flow","Brain Vascular Function","Satiety and Food Intake","Food Reward","Cognitive Performance","Abdominal Obesity",[257,258,259,260,261,262,263,264,179,265,266,267,268,269],"Walnuts","Juglans","Brain vascular function","Brain insulin sensitivity","Satiety","Food reward mechanisms","Cognitive performance","Abdominal obesity","pCASL MRI","fMRI","CANTAB","Intranasal insulin","Food cues","2026-07-23",{"date":224,"type":57},{"date":273,"type":57},"2025-10-01",{"date":275,"type":23},"2027-08",{"name":277,"class":64},"Maastricht University Medical Center",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":19,"minAge":286,"maxAge":242,"enrollmentInfo":287,"targetDuration":4,"studyType":24,"phases":289,"briefSummary":290,"conditions":291,"keywords":295,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":306,"locationsCount":65},"100527811","mind-foods-and-aerobic-training-in-black-adults-with-htn-100527811","NCT06152614","MIND Foods and Aerobic Training in Black Adults With HTN","MIND Foods and Aerobic Training in Black Adults With HTN: An ADRD Prevention Pilot RCT","MAT","Inclusion Criteria:\n\n1. Fluent in English\n2. Marion County resident\n3. 35-75 years\n4. Self-identified non-Hispanic and Black\u002FAfrican-American\u002Fbiracial including African-American\n5. Systolic BP of ≥140 in prior 12 months from a primary care visit\n6. Ability to see and read street signs (self report)\n7. Stable housing with independent access to kitchen, including functional stove or hotplate, oven, refrigerator, and freezer (self report)\n8. Activity independence per functional activities questionnaire (FAQ; \\\u003C3 responses of \"Require Assistance\" and 0 responses of \"Dependent\")\n9. Normal cognition per six-item screener (SIS; score of ≥ 5)\n10. Less than 20min on usual day of moderate or vigorous physical activity\n11. Able to exercise safely per abbreviated Exercise Assessment for You (EASY) or primary care provider clearance\n12. Mean systolic BP of ≥130 from 3 standard BP measurements taken by research staff following standardized wait periods.\n\nExclusion Criteria:\n\n1. lives in nursing home\n2. diagnosis of dementia or Alzheimer disease or mild cognitive impairment; Parkinson disease; brain tumor\u002Finfection\u002Fsurgery (within the last 10 years with residual symptoms and\u002For functional loss\u002Fdeficit, such as impaired learning, memory, or communication); cancer with short life expectancy, or current chemotherapy or radiation therapy; psychosis, schizophrenia, or bipolar disorder\n3. ICD 10 code I11\u002Fhypertensive heart disease, ICD 10 code I12\u002Fhypertensive CKD, ICD 10 code I13\u002Fhypertensive heart disease and CKD, ICD 10 code I15, or ICD 10 code I16\n4. current or past prescription of donepezil, memantine, rivastigmine, or galantamine\n5. alcohol consumption ≥ 8 drinks per week for women, or ≥15 drinks per week for men\n6. drug use\u002Fabuse (excluding marijuana) per EMR\n7. moving out of area during study timeline\n8. scheduling conflicts with intervention schedule\n9. unwilling to use a touchscreen\n10. unwilling to be on video conferencing\n11. low communicative ability, functional status, or other disorders (examiner rated) that would interfere with interventions and assessments\n12. unable to provide informed consent\n13. participation in any lifestyle modification\u002Fweight loss program (e.g., Weight Watchers, etc.)","35 Years",{"count":288,"type":23},128,[26],"The goal of this randomized controlled trial is to determine the impact of Mediterranean-Dash Intervention for Neurodegenerative Delay (MIND) diet and aerobic training on cognition in Black adults with high systolic blood pressure.\n\nResearchers will compare Food Delivery and Cooking PLUS Aerobic Training (FoRKS+) versus Enhanced Usual Care (EUC) to evaluate the effects on cognition.\n\nParticipants will complete cognitive and cardiovascular assessments, 24-hr blood pressure monitoring, standard blood pressure measurements, weight, fingerstick for HbA1c point-of-care testing, and questionnaires.\n\nParticipants may also choose to participate in an optional blood draw for DNA Repair Capacity testing as a modifiable risk factor for aging-associated diseases.",[34,292,293,294],"Hypertension","Diet","Aerobic Exercise",[296,297,298,299],"nutrition","cooking","exercise","hypertension","2026-07-21",{"date":302,"type":57},"2026-07-22",{"date":304,"type":57},"2023-11-28",{"date":196,"type":23},{"name":307,"class":64},"Indiana University",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":316,"minAge":317,"maxAge":4,"enrollmentInfo":318,"targetDuration":320,"studyType":100,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":4},"100648067","predictors-of-cognitive-decline-and-delirium-in-older-women-with-ovarian-cancer-100648067","NCT07716800","Predictors of Cognitive Decline and Delirium in Older Women With Ovarian Cancer","Identification of Clinical, Functional and Biological Predictors of Cognitive Decline and deliRium in Older Women Affected by Ovarian caNcer: the C.R.O.W.N. Study","CROWN","Inclusion Criteria:\n\n* Female sex with ovarian cancer.\n* Age ≥70 years.\n* Newly diagnosed ovarian cancer (any stage) or first disease recurrence.\n* Evaluation before initiation of any anticancer treatment or invasive procedure (e.g., primary cytoreductive surgery, neoadjuvant chemotherapy, image-guided biopsy, or exploratory laparoscopy).\n* Ability to understand and provide written informed consent, or availability of a legally authorized representative to provide consent.\n\nExclusion Criteria:\n\n* Age \\\u003C70 years.\n* Refusal or inability to provide written informed consent and absence of a legally authorized representative.","FEMALE","70 Years",{"count":319,"type":23},205,"12 Months","Cognitive decline and delirium are common geriatric syndromes that adversely affect treatment adherence, functional independence, quality of life, and survival in older adults with cancer. Women aged 70 years and older with ovarian cancer are particularly vulnerable because of the combined effects of aging, frailty, multimorbidity, and cancer-related factors. However, the prevalence, incidence, determinants, and longitudinal trajectories of cognitive impairment and delirium in this population remain poorly characterized, and validated strategies for risk stratification are lacking.\n\nThe C.R.O.W.N. (Identification of clinical, functional and biological predictors of Cognitive decline and deliRium in Older Women affected by ovarian caNcer) study is a prospective, single-center, longitudinal observational cohort study designed to identify clinical, functional, and biological predictors of cognitive decline and delirium in older women with ovarian cancer undergoing active treatment. Women aged 70 years or older with newly diagnosed ovarian cancer or first relapse will undergo a comprehensive geriatric assessment before treatment initiation and will be followed for 12 months. Assessments will include standardized cognitive and neuropsychological testing, frailty and functional evaluation, quality-of-life assessment, and systematic delirium screening during hospitalizations. Blood samples will be collected at baseline to measure biomarkers of neurodegeneration and inflammation. Telemonitoring will complement in-person follow-up visits to improve retention and longitudinal assessment.\n\nThe primary objective is to evaluate the prevalence, incidence, and trajectory of cognitive decline and to identify its clinical, functional, and biological predictors. Secondary objectives include evaluating the occurrence and predictors of delirium, assessing the impact of cognitive disorders on disability, hospitalization, mortality, and quality of life, and developing an integrated risk prediction model combining geriatric assessment and blood-based biomarkers. The study aims to improve early identification of patients at high risk for adverse cognitive outcomes and support personalized oncogeriatric care pathways.",[323,34,324],"Ovarian Cancer","Delirium","2026-07-16",{"date":300,"type":57},{"date":328,"type":23},"2026-09-01",{"date":330,"type":23},"2029-09-01",{"name":332,"class":64},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":19,"minAge":340,"maxAge":208,"enrollmentInfo":341,"targetDuration":4,"studyType":24,"phases":343,"briefSummary":344,"conditions":345,"keywords":346,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":353,"leadSponsor":355,"locationsCount":65},"100635025","effects-of-accelerated-rtms-on-cognitive-function-100635025","NCT07547319","Effects of Accelerated rTMS on Cognitive Function","Clinical and Neurophysiological Effects of Accelerated rTMS on Cognitive Function: A Prospective Pilot Study","Inclusion Criteria:\n\nEach potential subject must satisfy all of the following criteria to be enrolled in the study:\n\n* Subject must be 50 to 90 years of age, inclusive, on the day of signing informed consent.\n* Documented cognitive function decline, defined as:\n\nMoCA score of 10 to 25, inclusive (indicating mild to moderate cognitive impairment), OR Clinical diagnosis of mild cognitive impairment (MCI) or mild dementia based on established DSM-5 diagnostic criteria.\n\n* Ability to provide written informed consent, or availability of a legally authorized representative to provide consent.\n* Subject must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.\n* Sufficient visual and auditory acuity to complete cognitive assessments.\n* Stable doses of any cognitive-enhancing medications (e.g., cholinesterase inhibitors, memantine) for at least 4 weeks prior to screening, with no anticipated changes during the study period.\n* Availability and willingness to complete all scheduled study visits.\n* Presence of a reliable study partner or caregiver who can provide information about the participant's cognitive and functional status.\n* Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb.\n* Subjects willing and able to abstain from partaking in any treatments other than the study procedure for the improvement in cognitive function, including non-invasive brain stimulation treatments other than the study procedure during study participation.\n* Subjects willing and able to maintain their regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation.\n* Willingness to comply with study instructions and to return to the clinic for the required visits.\n* Women of child-bearing potential are required to use birth control measures during the whole duration of the study.\n\nExclusion Criteria:\n\nAny potential subject who meets any of the following criteria will be excluded from participating in the study:\n\n* Electronic implants in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants in or near the head including device leads, deep brain stimulators, cochlear implants, ocular implants, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, and neurostimulators.\n* Metallic, ferromagnetic, or other magnetic-sensitive implants\u002Fobjects in or near the head - rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic, or other magnetic-sensitive metals implanted in their head (with some exceptions in the mouth - see Operator's Manual) or within 12 inches (30 cm) of the therapy coil. Examples include implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, bullet fragments, jewelry, hair barrettes, and tattoos with metallic ink.\n* Drug pumps within 12 inches (30 cm) of the therapy coil.\n* Inability to determine the motor threshold of the participant (i.e., the minimum stimulus required to induce contraction of the right thumb cannot be established).\n* History of seizure disorder or epilepsy, except for a single remote seizure more than 5 years ago, which may be permitted at investigator discretion.\n* Elevated risk of seizure due to traumatic brain injury with loss of consciousness \\>30 minutes within the past 12 months.\n* Current use of medications known to significantly lower seizure threshold (e.g., clozapine, bupropion at doses \\>450 mg\u002Fday, theophylline, high-dose tricyclic antidepressants) or recent dose reduction of anticonvulsant medications or benzodiazepines within 4 weeks of screening.\n* Severe dementia, defined as MoCA score below 10, or inability to follow simple verbal commands or complete basic cognitive assessments.\n* Rapidly progressive dementia (e.g., suspected prion disease, autoimmune encephalitis).\n* Brain tumor, intracranial hemorrhage within the past 12 months, arteriovenous malformation, or increased intracranial pressure.\n* Acute stroke within the past 3 months (stable chronic stroke with cognitive sequelae may be included at investigator discretion).\n* Has a current diagnosis of psychotic disorder, bipolar disorder, or other psychiatric condition that, in the investigator's opinion, would interfere with the subject's ability to participate in the trial.\n* Has a current or recent history of serious suicidal ideation within the past 6 months, corresponding to a positive response on item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS, or a history of suicidal behavior within the past year, as validated by the C-SSRS at screening.\n* History of substance or alcohol use disorder of moderate to severe severity according to DSM-5 criteria within 6 months before screening, or positive test result(s) for drugs of abuse (including opiates, cocaine, cannabinoids, methamphetamines, amphetamines) at screening.\n* Has history of or current clinically significant and\u002For unstable medical condition that could interfere with study participation or pose safety concerns, including but not limited to:\n\nModerate or severe hepatic impairment (Child-Pugh Score ≥7) Severe renal impairment (estimated creatinine clearance below 30 mL\u002Fmin or serum creatinine \\>2 mg\u002FdL) Unstable cardiac, vascular, or pulmonary disease Note: Subjects with chronic but stable, well-controlled conditions may be allowed in the study upon agreement with the investigator.\n\n* Has uncontrolled hypertension (systolic blood pressure \\>160 mm Hg or diastolic blood pressure \\>100 mm Hg, despite diet, exercise, or a stable dose of antihypertensive therapy) at screening. A subject with hypertension may be included if the subject's hypertension has been controlled for at least 3 months prior to screening, and the dosage of any antihypertensive medication has been stable for the past 3 months.\n* Has clinically significant ECG abnormalities at screening, defined as:\n\nQTc interval (Fridericia's formula): ≥450 msec (males); ≥470 msec (females) Evidence of 2nd or 3rd degree atrioventricular block, or 1st degree atrioventricular block with PR interval \\>210 msec Left bundle branch block Features of new ischemia Other clinically important arrhythmia Note: Subjects with right bundle branch block may be allowed provided confirmation that right bundle branch block is not associated with underlying cardiac\u002Flung diseases.\n\n\\- Has a known malignancy or history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that, in the opinion of the investigator, is considered cured with minimal risk of recurrence).\n\nHad clinically significant acute illness within 7 days prior to study rTMS treatment.\n\n\\- Had major surgery (e.g., requiring general anesthesia) within 2 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study.\n\nNote: Subjects with planned surgical procedures to be conducted under local anesthesia may participate.\n\n* Is pregnant or breastfeeding while enrolled in this study or within 1 month after the last session of study rTMS treatment.\n* Has received an investigational drug or used an invasive investigational medical device within 3 months before screening, or is currently enrolled in an investigational study.\n* Prior treatment with rTMS within 6 months of screening.\n* Subjects willing to partake in any treatments other than the study procedure for the improvement in cognitive function, including non-invasive brain stimulation treatments other than the study procedure, during study participation.\n* Has psychological and\u002For emotional problems which would render the informed consent invalid, or limit the ability of the subject to comply with the study requirements.\n* Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.\n* Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.\n\nNOTE: Investigators should ensure that all study enrollment criteria have been met at screening. If a subject's clinical status changes after screening but before the first rTMS treatment session such that he or she no longer meets all eligibility criteria, then the subject should be excluded from participation in the study.","50 Years",{"count":342,"type":23},80,[26],"Cognitive impairment, including mild cognitive impairment (MCI) and mild dementia, is a growing public health challenge with limited effective treatment options. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that has shown promise for improving cognitive function, but most studies have used conventional protocols and relied on global screening tools that may not capture domain-specific changes.\n\nThe purpose of this study is to evaluate the efficacy and tolerability of repetitive transcranial magnetic stimulation (rTMS) delivered via the EXOMIND™ device (BTL-699-2) for improving cognitive function in adults aged 50 to 90 years with mild to moderate cognitive impairment. The study asks whether a course of 6 rTMS sessions targeting the left dorsolateral prefrontal cortex, administered twice weekly over approximately 3 weeks, can produce meaningful and sustained improvements in global and domain-specific cognitive function over a 3-month follow-up period.\n\nThis is a single-center, open-label, prospective pilot study enrolling 80 participants with documented cognitive decline (Montreal Cognitive Assessment \\[MoCA\\] score 10-25). Participants will receive 6 sessions of high frequency rTMS (6,300 pulses per session at alternating frequencies of 12, 15, and 18 Hz) over approximately 3 weeks. The primary outcome is the change from baseline in MoCA score at 1-month follow-up. Secondary outcomes include changes in MoCA score at post-treatment and 3-month follow-up, changes in domain-specific cognitive measures (visual spatial working memory, episodic memory, deductive reasoning, mental rotation, verbal short term memory, and attention) assessed by the Creyos cognitive battery, and changes in depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9). Assessments are performed at baseline, post treatment, 1-month follow-up, and 3-month follow-up. Total study duration per participant is up to 139 days.",[34,104],[347,348,34,137],"rTMS","ExoMind","2026-07-15",{"date":351,"type":57},"2026-07-17",{"date":349,"type":23},{"date":354,"type":23},"2027-12-31",{"name":356,"class":64},"San Francisco Neurology and Sleep Center",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":18,"sex":19,"minAge":364,"maxAge":365,"enrollmentInfo":366,"targetDuration":4,"studyType":24,"phases":368,"briefSummary":369,"conditions":370,"keywords":371,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":65},"100515939","a-mechanistic-study-to-investigate-tdcs-and-working-memory-in-mci-patients-100515939","NCT05998031","A Mechanistic Study to Investigate tDCS and Working Memory in MCI Patients","AIM","Inclusion Criteria\n\n* Age 60-95 years\n* Montreal Cognitive Assessment (MoCA) score 18 and above (scores will be adjusted for education)\n* Able to receive electrical stimulation\n* Ability to comprehend conversational voices\n* Adequate motor capacity to operate computer mouse and click-button in-scanner\n* Ability to participate in the intervention and attend training sessions Exclusion Criteria\n* Failure to provide informed consent\n* Contraindications to MRI recording (e.g., any kind of ferrous metallic stents or ferrous metal objects in the body, heart valve prosthesis, or other metal implants, claustrophobia, neurostimulation system, defibrillator, pacemaker, or other implanted device)\n* Left-handed, or left hand dominant\n* History of neurological, seizures, and psychiatric disorders, traumatic brain injury, incidence of stroke involving large vessel\n* Terminal illness with life expectancy less than 12 months, as determined by physician\n* Brain tumor or malformation or any foreign body known or previously identified in brain\n* Cancer in active treatment, besides skin cancer\n* Currently on GABAergic or glutamatergic medications, or on calcium or sodium channel blockers, which alter or block the ability of tDCS to facilitate tissue excitability\n* Unable to communicate because of severe hearing loss or speech disorder\n* Severe sensory impairment\n* Inability to communicate in English\n* Severe visual impairment, which would preclude completion of the assessment and\u002For intervention\n* No physical impairment precluding motor response or lying still for an hour in the scanner that could confound study findings\n* Moderate-to-severe depressive symptoms as defined by scoring 10 or above on the Geriatric Depression Scale (GDS)","60 Years","95 Years",{"count":367,"type":23},110,[26],"The current study is a mechanistic study to evaluate working memory gains from application of transcranial direct current stimulation (tDCS) in older adults with mild cognitive impairments (MCI) compared to cognitively healthy control",[104,34],[372,373,374,375,376],"Cognitive Aging","Brain Stimulation","functional MRI","Computational Modeling","Finite Element Method (FEM)","2026-06-25",{"date":379,"type":57},"2026-06-26",{"date":381,"type":57},"2024-04-24",{"date":383,"type":23},"2029-11-30",{"name":385,"class":64},"University of Florida",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":19,"minAge":394,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":397,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":65},"100642364","using-artificial-intelligence-to-detect-early-signs-of-alzheimers-disease-in-people-with-memory-concerns-100642364","NCT07652931","Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns","AHEAD: AI-driven Brain Health for Early Alzheimer's Disease Detection in Individuals With Subjective Cognitive Decline","AHEAD","Inclusion Criteria:\n\n1. Diagnosis of Subjective Cognitive Decline (SCD) according to international diagnostic criteria (Jessen et al., 2014).\n2. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event.\n3. Normal age-, gender-, and education-adjusted performance on standardized cognitive tests used to classify mild cognitive impairment (MCI) or prodromal AD.\n4. Age greater than or equal to 40 years.\n5. Native Italian Speaker.\n6. Stable pharmacological treatment for at least 4 weeks prior to enrollment.\n7. Provision of oral and written informed consent to study participation.\n\nExclusion Criteria:\n\n1. Presence of MCI, prodromal AD, or dementia.\n2. Any major systemic, psychiatric, or neurological disturbance.\n3. Medical conditions or substance abuse that could interfere with cognition.\n4. Pacemaker and\u002For other implanted neurostimulation devices in the head\u002Fneck district.\n5. Contraindications to undergoing MRI examination.\n6. Brain damage at routine MRI, including extensive cerebrovascular disorders.\n7. Traumatic or surgical wounds that could determine a risk of infection at the site of non-invasive stimulation.\n8. Scalp alterations that could determine the spread of excessive current from the device.\n9. Known history of epilepsy (due to small risk of seizure induction from rTMS in epileptic patients).\n10. Denial of oral and written informed consent to study participation.","40 Years",{"count":396,"type":23},300,[26],"AHEAD is a prospective, longitudinal, risk-stratified single-arm interventional study enrolling 300 patients with Subjective Cognitive Decline (SCD) at IRCCS San Raffaele Hospital, Milan, Italy.\n\nThe study uses artificial intelligence (AI) to integrate multimodal data - including MRI, EEG, Optical Coherence Tomography (OCT), neuropsychological assessments, and plasma biomarkers - to identify individuals with underlying Alzheimer's disease (AD) biology and predict cognitive progression.\n\nOnly participants found to be AD plasma biomarker positive (SCD+) undergo longitudinal follow-up at 12 and 24 months. Participants classified as high risk additionally receive a 6-month personalized multidisciplinary intervention combining high-frequency transcranial magnetic stimulation (TMS), digital cognitive training, structured physical exercise, and targeted management of modifiable vascular and behavioral risk factors.",[400,180,139,34],"Subjective Cognitive Decline",[400,402,403,404,405,406,407,408,409,410,411,40,412,413,414],"Alzheimer's disease","Artificial Intelligence","Transcranial Magnetic Stimulation","Plasma biomarkers","p-tau217","MRI","EEG","Optical Coherence Tomography","Cognitive Training","Physical Exercise","APOE","Machine Learning","Deep Learning","2026-06-11",{"date":417,"type":57},"2026-06-17",{"date":419,"type":23},"2026-08-01",{"date":421,"type":23},"2029-08-01",{"name":423,"class":64},"IRCCS San Raffaele",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":19,"minAge":430,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":24,"phases":433,"briefSummary":434,"conditions":435,"keywords":441,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":233},"100608933","evaluating-health-outcomes-of-ai-based-fitness-wearables-and-app-programs-in-older-adults-living-alone-with-cognitive-decline-100608933","NCT07207993","Evaluating Health Outcomes of AI-Based Fitness Wearables and App Programs in Older Adults Living Alone With Cognitive Decline","Inclusion Criteria:\n\n* Participant must be at least 65 years of age older\n* Participant must be living alone in the U.S. for the next 6 months\n* Participant must have report mild cognitive decline \\[We will use a short self-report AD8 measure of cognitive concerns. Those scoring positive on the AD8 (≥2) will qualify as mild cognitive decline\\];\n* Participant must own an Android\u002FApple smartphone\n* Participant must have access to internet or Wi-Fi access\n* Participant must be capable of engaging in some PA as determined by the PA Readiness Questionnaire or physician approval\n* Participant must currently participate in weekly moderate-to-vigorous PA (MVPA) or less than 150 minutes\n* Participant must have basic English communication skills.\n\nExclusion Criteria:\n\n* Foreign residents or visitors","65 Years",{"count":432,"type":23},64,[26],"The overarching goal of our research is to develop personalized and accessible healthy aging lifestyle interventions aimed at promoting physical activity (PA) and improving health among community-dwelling older adults living alone with cognitive decline (LACD). To achieve this goal, the purpose of this project is to determine whether wearable and app-based mHealth intervention component(s) will contribute to increased PA and improved health outcomes in older adults LACD. Our specific aims are to: identify and evaluate mHealth intervention components that practically and significantly contribute to enhanced mechanistic outcomes (e.g., self-efficacy, outcome expectations) and increased PA (primary outcome) in older adults LACD over a 6-month period; determine the optimal combinations of intervention components for future efficacy testing; elucidate the mechanism of behavioral change (MoBC) and potential outcomes of these intervention components, namely, the mediating effects of MoBC variables (e.g., self-efficacy, outcome expectations) on the relationship between intervention components and change in PA. The first two aims are primary and fully-powered. The third aim is exploratory. The aims will support a refined, data-driven intervention design for a subsequent larger trial.",[436,437,438,439,34,45,440],"Older Adults With Cognitive Decline","Older Adults","AI-Based Fitness","Wearables","Physical Inactivity",[442,179,438,45,440,443,444,445],"Older adults","Living alone with cognitive decline","LACD","U.S Older adults","2026-06-10",{"date":448,"type":57},"2026-06-15",{"date":450,"type":57},"2026-06-08",{"date":452,"type":23},"2028-06-08",{"name":454,"class":64},"The University of Tennessee, Knoxville",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":18,"sex":19,"minAge":131,"maxAge":430,"enrollmentInfo":463,"targetDuration":4,"studyType":24,"phases":465,"briefSummary":466,"conditions":467,"keywords":468,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":233},"100602780","exercise-adherence-and-cognitive-decline-phase-2-100602780","NCT07127965","Exercise Adherence and Cognitive Decline: Phase 2","Exercise Adherence and Cognitive Decline: A Goal-setting and Exercise Intensity Intervention Collaboratively Developed With the Black Community","MOVE","Inclusion Criteria:\n\n* \\\u003C3 incorrect responses on the Pfeiffer Mental Status Questionnaire\n* Ages 45 to 65\n* Consent to be randomized to conditions\n* Planning to remain in the Denver metro area for the next 14 months\n* Identify as Black or African American\n\nExclusion Criteria:\n\n* Currently physically active (i.e., \\>90 min\u002Fweek of moderate PA or \\>40 min\u002Fweek of vigorous PA consistently for the past 6 months)\n* On antipsychotic medications or currently under treatment for any serious psychiatric disorder including Alzheimer's or dementia\n* Inability to walk 3 blocks without chest pain, shortness of breath, or lightheadedness\n* Inability to climb 2 flights of stairs without chest pain, shortness of breath, or lightheadedness\n\nPCP Exclusion Criteria:\n\n* Answers \"yes\" to 1 or more of the 7 general questions of the PAR-Q+ and answers yes to any of the follow up questions.\n* Blood pressure at baseline is greater than 160\u002F100\n* Blood pressure at baseline is between 140\u002F90 - 160\u002F100 and the participant is currently taking blood pressure medication\n* Blood pressure \\> 210\u002F90 mmHg (for men) or \\> 190\u002F90 mmHg (for women) immediately after exercise",{"count":464,"type":23},226,[26],"The purpose of this study is to conduct a test of a goals-based program to help people exercise more. This program was designed for individuals aged 45-65 from the Black community. Low levels of physical activity are related to health problems such as heart disease, diabetes, and cognitive decline. People of color are more negatively impacted by these conditions and have also historically been underrepresented by research seeking to increase physical activity. The investigators have developed this goals-based exercise promotion program with the help of a Black-led community-based organization (The Gyedi Project) and a Community Advisory Board made up of stakeholders in the Black community.",[34],[469,470,471,34],"Goals","Goal Difficulty","Exercise Intensity","2026-06-09",{"date":415,"type":57},{"date":475,"type":57},"2025-11-05",{"date":477,"type":23},"2028-08-31",{"name":479,"class":64},"University of Colorado, Boulder",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":18,"sex":19,"minAge":340,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":24,"phases":489,"briefSummary":490,"conditions":491,"keywords":492,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":65},"100555066","polyphenols-and-cognitive-decline-100555066","NCT06507254","Polyphenols and Cognitive Decline","MAEVE: Microbiota Mediated Flavonoid Metabolites for Cognitive Health","MAEVE","Inclusion Criteria:\n\n* 50+ Years of age\n* Male or Female\n* At enhanced risk of Alzheimer's Disease (defined as family history of AD, 1st degree family member)\n* Habitually consume suboptimal diets such as typical Western Diet (i.e., high in animal products, refined carbohydrates and processed food)\n* Able to communicate well in English\n\nExclusion Criteria:\n\n* Vegan or Vegetarian\n* Presence of cognitive impairment at the time of recruitment into the study as measured by the Mini Mental Status Exam (MMSE, score 25-30) and Clinical Dementia Rating (CDR, score=0).\n* Pre-existing psychosis or psychiatric conditions\n* Currently receiving treatment for dementia\n* History of alcohol and\u002For substance abuse\u002Fdependence as determined by a positive endorsement on the MINI+\u002F If the MINI+ is positive for alcohol or drug dependence, or abuse, the participants will be excluded.\n* Heavy use of tobacco (greater than 1\u002F2 pack per day)\n* History of cerebrovascular events\n* Existing allergies to berry fruits\n* Use of oral\u002FIV antibiotics in the last 3 months. Use of probiotics in the last 1 month.\n* Recent Changes (last 3 months) in the use of psychoactive medications or other medications that interfere with the measured outcomes.\n* Frailty, malnutrition, or food allergy\u002Fintolerance requiring special diets.\n* Body weight at enrollment greater than 400lbs due to weight restrictions on the MRI table.\n* Women who are pregnant, lactating, or postpartum for less than 6months.\n* Women of childbearing age who are not practicing birth control or are planning to get pregnant during the study.\n\nUnable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, metallic foreign body, etc.)\n\n* Chronic Pain",{"count":396,"type":23},[26],"Globally, populations are aging thereby increasing healthcare burden, overall cognitive impairment, and dementia including Alzheimers diseases (AD). The lack of effective treatments makes it essential to develop new strategies for healthy cognitive aging, including interventions to slow or prevent cognitive decline. A traditional Mediterranean diet, rich in polyphenols (PPs), may prevent or delay the onset of cognitive dysfunction in older adults, preserving healthy brain structure and function, and lowering the risk of AD. These effects, mediated in part by gut microbiome-derived PP metabolites, highlight the role alterations in the brain-gut microbiome system play in neurodegeneration. Moreover, high levels of circulating phenyl-y-valerolactones, neuroprotective compounds, exclusively produced by gut microbiota from flavan-3-ol-rich foods (e.g., cocoa, tea, berries) are associated with delaying the onset of cognitive dysfunction in older adults. Intake of such PPs can also change gut microbial composition and function, altering the physiology of the hosts secondary bile acid (BA) pool, affecting regulatory and signaling functions in the brain as well as cognitive decline and AD. The investigators hypothesize that, in older adults with enhanced AD risk, dietary intake of PPs maintains healthier brain features and cognitive function, and that this beneficial effect is mediated by gut microbiota metabolites of PPs and BAs.\n\nIn this multi-PI application by leaders in the field of brain-gut microbiome interactions, the investigators will conduct a year-long, multi-center, randomized double-blind placebo-controlled study in 300 older adults in the United States (validation sample of 100 from Northern Ireland) who are at enhanced risk of developing AD. Ultimately, the investigators will establish the protective effects of regular dietary PP intake on cognitive function and on brain-gut microbiome interactions, ideally allowing the development of effective dietary regimes to prevent of delay the onset of AD in at-risk elderly, thereby reducing cognitive decline and healthcare costs.\n\nParticipants will be asked to provide information about their diet, mood, and behaviors via food diaries, physical body measures (e.g. height, weight, etc.), and online questionnaires collected before each in-clinic appointment, as well as monthly online questionnaires. MR imaging will be collected on participants to assess neurocognitive changes as a result of the supplement. Participants will be asked to provide both stool and blood samples. Participants will be randomly assigned to either the Juice Plus+ intervention group or the placebo treatment group and then asked to take their respective supplement 4 pills twice a day. All participants will be asked to come in for 4 in-clinic appointments, including 3 brain MRI scans and 3 cognitive testing appointments, collect 3 stool samples with corresponding diet diaries, and provide 3 blood samples over the course of 12 months. Participants will also meet with a nutritionist 3 times over the 12 months to discuss diet to ensure study eligibility and any questions about the supplement.",[34,105],[493,494,495,496],"Polyphenols","Mediterranean Diet","Gut Microbiome","Alzheimers Disease",{"date":415,"type":57},{"date":499,"type":57},"2025-01-09",{"date":501,"type":23},"2029-12-31",{"name":503,"class":64},"University of California, Los Angeles",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":19,"minAge":364,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":512,"conditions":513,"keywords":515,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":527,"leadSponsor":529,"locationsCount":65},"100637415","effects-of-comprehensive-community-support-programs-on-cognitive-function-and-quality-of-life-in-older-adults-100637415","NCT07610109","Effects of Comprehensive Community Support Programs on Cognitive Function and Quality of Life in Older Adults","THE EFFECTS OF COMPREHENSIVE COMMUNITY SUPPORT PROGRAMS FOR THE ELDERLY ON COGNITIVE FUNCTIONS AND QUALITY OF LIFE: THE VEFAHANE MODEL","Inclusion Criteria:\n\n* Elderly individuals aged 60 and over who attend or will attend Vefahane Life Center\n* Able to cooperate,\n* Individuals who speak Turkish\n* Individuals who are literate\n\nExclusion Criteria:\n\n* Individuals previously diagnosed with dementia,\n\n  * Individuals with neurological and psychiatric diagnoses that affect cognitive skills,\n  * Individuals receiving occupational therapy interventions aimed at improving cognitive skills within the center,\n  * Individuals with illnesses that prevent participation in the activity program (cancer, cardiovascular instability, etc.),\n  * Individuals with severe visual and hearing loss that hinders communication.",{"count":22,"type":23},"This prospective observational study aims to investigate the effects of a multidomain community-based support program on cognitive function and quality of life in older adults attending the Vefahane Life Center in Istanbul, Türkiye. The study will compare elderly individuals actively participating in community-based social, cognitive, physical, and supportive activities with individuals registered at the center but not actively participating during the study period. Participants will undergo neuropsychological and psychosocial assessments at baseline and after 3 months. The primary outcome is change in global cognitive performance measured by the Mini Mental State Examination (MMSE). Secondary outcomes include memory, executive functions, depression, neuropsychiatric symptoms, and quality of life measures.",[34,215,514],"Quality of Life",[516,517,518,519,520,521,522],"older adults","aging","cognitive rehabilitation","cognitive function","community-based intervention","social wellbeing","social participation","2026-05-20",{"date":525,"type":57},"2026-05-27",{"date":523,"type":57},{"date":528,"type":23},"2026-12-30",{"name":530,"class":64},"Istanbul Medipol University Hospital",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":19,"minAge":317,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":540,"conditions":541,"keywords":542,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":65},"100283625","identification-of-epigenetic-risk-factors-for-ischemic-complication-during-the-tavr-procedure-in-the-elderly-100283625","NCT02972008","Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly","METHYSTROKE","Inclusion Criteria:\n\n* Patients over 70 years with severe aortic stenosis requiring percutaneous aortic valve replacement (TAVI)\n\nExclusion Criteria:\n\n* Patient contraindicated for the TAVI procedure\n* Patient with a pace-maker\n* Patient with contra-indication for cerebral MRI\n* Ongoing cancer\n* Patient already involved in therapeutic research\n* Major persons under protection of justice.",{"count":539,"type":23},542,"Over the past ten years, the number of endovascular procedures has increased by 5% per year in Europe with the development of interventional cardiology, such as percutaneous coronary angioplasty, aortic valve replacements (TAVR), and vascular endoprosthesis.\n\nThe neurological lesions detected on cerebral MRI caused by these endovascular procedures are frequent with an incidence of about 30-70%. These events, although subclinical, have an impact on morbidity and mortality and especially on long-term cognitive decline.\n\nTAVR is the reference treatment for symptomatic elderly patients with stenosis of the aortic valve, considered by a multidisciplinary \"Heart Team\" as at high surgical risk due to comorbidities, age and high perioperative risk scores ( Euroscore 2 and STS scores). Despite the net clinical benefit, an increase of silent neurological events was detected on post-procedural cerebral MRI with an incidence of approximately 70%.\n\nThe epigenetic involvement in the occurrence of ischemic cerebral lesions is still largely unknown. Epigenetic mechanisms, such as DNA methylation, can be associated with aging processes and modulate the risk of developing cerebrovascular pathologies. They are likely to provide new biomarkers that predict the risk of brain damage.\n\nHypomethylation of leukocyte DNA is directly related to atherosclerosis in humans. This hypomethylation of DNA would represent an easily measurable marker reflecting the presence and progression of atherosclerosis. Because atherosclerotic lesions often precede the clinical manifestation of ischemic cardiovascular disease, such as ischemic heart disease and stroke, DNA hypomethylation could be used to identify individuals at risk for cerebrovascular events.\n\nThe investigator hypothesize that hypomethylation of leukocyte DNA can predict the risk of developing new ischemic brain lesions especially after a TAVI procedure.",[34,31],[543,544,545,546],"Aortic stenosis","Transaortic valve replacement","stroke","Epigenetic",{"date":548,"type":57},"2026-05-22",{"date":550,"type":57},"2017-03-09",{"date":552,"type":23},"2027-02",{"name":554,"class":64},"University Hospital, Lille",{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":562,"enrollmentInfo":563,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":65},"100411294","cognitive-status-after-removal-of-skull-base-meningioma-100411294","NCT04635657","Cognitive Status After Removal of Skull Base Meningioma","Pre and Post-Operative Cognitive Status in Patients Undergoing Surgery for Resection of Meningioma Associated With the Frontal and Temporal Lobes","Inclusion Criteria:\n\n* Subject has a meningioma associated with the frontal or temporal lobes\n* Subject is scheduled to undergo open craniotomy or Endoscopic Endonasal surgery\n* Subject is 18 years of age or older\n* The subject must in the investigator's opinion, be psychosocially, mentally, and physically able to fully comply with this protocol including the required follow-up visits, the filling out of required forms, and have the ability to understand and give written informed consent\n* Previous surgery will not exclude the patient as a new baseline cognitive evaluation will occur.\n\nExclusion Criteria:\n\n* Patient is a prisoner\n* Patient is 90 years of age or older\n* Pregnant women\n* Previous radiation to the brain","89 Years",{"count":564,"type":23},50,"The purpose of this prospectively enrolling trial is to assess long-term cognitive outcomes of patients undergoing surgery for resection of a meningioma associated with the frontal and temporal lobes.",[567,568,569,570,104,34,571],"Meningioma","Skull Base Meningioma","Frontal Meningioma","Temporal Meningioma","Post-Surgical Cognition","2026-05-19",{"date":548,"type":57},{"date":575,"type":57},"2019-12-10",{"date":577,"type":23},"2028-12-31",{"name":579,"class":64},"Ohio State University",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":18,"sex":316,"minAge":587,"maxAge":364,"enrollmentInfo":588,"targetDuration":4,"studyType":24,"phases":589,"briefSummary":590,"conditions":591,"keywords":599,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":65},"100639704","algal-lutein-against-decline-of-intellectual-nimbleness-100639704","NCT07600567","Algal Lutein Against Decline of Intellectual Nimbleness","ALADIN","Inclusion Criteria:\n\n* Females\n* Age 48-60 years\n* Postmenopausal status (natural menopause, up to 5 years after menopause)\n* waist circumference ≥ 88 cm\n\nExclusion Criteria:\n\n* Diagnosis of dementia or cognitive impairment\n* Use of hormone replacement therapy within the last 6 months\n* Advanced age-related macular degeneration\n* History of major untreated neurological or psychiatric disorders (including depression, Parkinson's disease, Alzheimer's disease, psychiatric disorders, stroke within the last 3 months)\n* Presence of chronic diseases, including: diabetes mellitus (type 1 or 2), lipid disorders, cardiovascular diseases, thyroid diseases, anemia, liver diseases, gastrointestinal disorders, or cancer within the last 5 years\n* Use of anti-inflammatory medications or medications targeting lipid or carbohydrate metabolism within the last 3 months\n* Alcohol consumption \\> 100 g per week\n* Use of lutein-containing supplements","48 Years",{"count":396,"type":23},[26],"Lutein is a xanthophyll pigment found in photosynthesizing organisms. Its beneficial effects on health, including brain function and visual performance, have been recognized for many years. However, to date, only a limited number of well-designed human intervention studies have been published regarding the effects of incorporating lutein into the daily diet (as humans are unable to synthesize lutein endogenously). Unfortunately, within the Western dietary pattern, the average daily intake of lutein is approximately 1.7 mg, whereas achieving health benefits- such as reducing the risk of age-related macular degeneration and cataract, as well as neurodegenerative diseases- requires an intake of 6 to 14 mg per day.\n\nIn light of the above, it is therefore justified to enrich the daily diet with products that are sources of lutein. Unfortunately, the consumption of dark green vegetables- the richest dietary source of lutein-remains insufficient. Lutein preparations currently available on the market are extracted from marigold or calendula flowers. However, lutein production from these raw materials requires greater water consumption and land use, which is not aligned with the principles of sustainable development. An alternative approach involves the production of lutein preparations from microalgae (from species approved as food by the European Food Safety Authority, EFSA), as the rate of lutein production from microalgae is three to six times higher than that from marigold flowers.\n\nTaking the above into account, the primary objective of this project is to evaluate the dose-response relationship in establishing the anti-aging mechanism of action of lutein derived from microalgae.\n\nAs part of the project, a six-month randomized, placebo-controlled trial is planned. The study will include 300 polish women (aged 48-60 years), after natural menopause, with visceral obesity (waist circumference ≥ 88 cm). In order to enable the inclusion of such a large study population, the research team will conduct intensified recruitment efforts for several months prior to the initiation of the dietary intervention.\n\nParticipants who meet the inclusion criteria will be randomly assigned to one of three groups: lutein supplementation at a dose of 6 mg (n = 100), lutein supplementation at a dose of 14 mg (n = 100), or placebo (n = 100). The volunteers will be instructed to take the prescribed preparation daily for 180 days. All preparations will be identical in appearance, taste, and smell.\n\nAll volunteers expressing willingness to participate in the experiment will be asked to provide written informed consent prior to enrollment in the study.\n\nThe study will be conducted in accordance with the previously calculated sample size (n = 300 postmenopausal women with visceral obesity). In order to obtain a homogeneous study population, appropriate inclusion and exclusion criteria will be applied.\n\nConducting the research in such a large and homogeneous group will enable the generation of high-quality scientific evidence identifying the dose of microalgae-derived lutein that allows for the determination of its anti-aging mechanism of action. It will also be possible to elucidate the potential role of short-chain fatty acids (SCFAs) in feces in this process, which may represent a significant novelty in this field of research.\n\nThe study will contribute to the development of new knowledge regarding the anti-aging properties of lutein derived from microalgae in populations vulnerable to cognitive impairment (postmenopausal women). However, microalgae-derived lutein may be used as a dietary supplement not only in the studied group but also in the general population.\n\nThe specific objectives are as follows:\n\n* To assess the effect of lutein derived from microalgae (at doses of 6 mg and 14 mg) on the concentration of brain-derived neurotrophic factor (BDNF), inflammatory markers, cardiometabolic parameters, fecal short-chain fatty acid (SCFA) concentrations, and cognitive function in postmenopausal women with visceral obesity.\n* To evaluate adherence to lutein supplementation recommendations (by assessing macular pigment optical density).\n* To determine whether supplementation with microalgal lutein increases fecal SCFA concentrations and whether SCFAs may act as mediators in improving inflammatory markers and cognitive function in postmenopausal women with visceral obesity.\n* To determine whether supplementation with microalgal lutein (at doses of 6 mg and 14 mg) affects changes in selected gut bacterial populations and β-glucuronidase enzymatic activity in postmenopausal women with visceral obesity.\n* To analyse the association between polymorphisms in genes related to lutein metabolism and transport in the body and the effectiveness of supplementation with this compound.\n* To identify dietary behaviour patterns associated with high exposure to bisphenol A (BPA) and the presence of inflammation in postmenopausal women with visceral obesity.",[592,34,593,594,595,596,597,598],"Menopausal Syndrome","Obesity & Overweight","Menopause","Inflamation","Gut Dysbiosis","Bisphenol A","Cardio Vascular Disease",[600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617],"menopausal syndrome","cognitive decline","obesity","menopause","inflammation","dysbiosis","bisphenol A","gut microbiota","BNDF","intellectual nimbleness","beta-glucuronidase","lutein","supplementation","micro-algae","gene polimorfism","eye vision","chlorella","sustainable development","2026-05-13",{"date":523,"type":57},{"date":621,"type":23},"2026-05-01",{"date":623,"type":23},"2027-04-30",{"name":625,"class":64},"Poznan University of Life Sciences",{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":24,"phases":635,"briefSummary":637,"conditions":638,"keywords":641,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":4},"100485768","phase-1-minocycline-in-neurocognitive-outcomes---sickle-cell-disease-100485768","NCT05605366","Minocycline In Neurocognitive Outcomes - Sickle Cell Disease","MINO-SCD","Inclusion Criteria:\n\nAdults (age ≥ 18 years old) with SCD (HbSS and HbS-β0thalassemia genotypes only) who are followed at the University of Cincinnati Medical Center's SCD clinic are eligible to participate. As hydroxyurea is the standard-of-care in SCD, individuals on hydroxyurea will be included\n\nExclusion Criteria:\n\n1. adults with other SCD genotypes (HbSC or HbS- β+thalassemia),\n2. individuals with a history of overt stroke or other known neurological disorder,\n3. premature birth before 30 weeks gestation,\n4. monthly therapy with chronic blood transfusions,\n5. coexisting autoimmune condition due to an elevated risk for autoimmune-related complications with tetracyclines,\n6. tetracycline allergy.\n7. Women who are pregnant or breast-feeding",{"count":634,"type":23},30,[636],"PHASE1","Sickle cell disease (SCD) is a common, inherited blood disorder that primarily affects people of African Ancestry. It has a lot of complications including neurological complications. The neurological complications of SCD are particularly devastating and lead to cognitive decline even in the absence of overt brain injury. In such cases, it is thought that inflammation in the brain maybe partly responsible for the cognitive decline.\n\nThe main reasons for this research study are to see 1) how safe and 2) how well minocycline works to try to stop\u002Freverse cognitive decline in people with SCD. People with SCD are at risk for changes in their brain over time that can cause problems with learning, memory, and attention. Part of the reason for this is inflammation within the brain. Minocycline may be able to stop these brain changes by stopping this brain inflammation.\n\nMinocycline is a second-generation tetracycline antibiotic that has been shown to both inhibit neuroinflammation and improve cognitive function in a variety of neurodegenerative and psychiatric disorders but has not yet been studied in SCD. We are proposing here, a pilot double-blinded, randomized controlled trial to examine the tolerability and early efficacy of minocycline in adults with SCD at two dosing regimens (200 mg and 300 mg daily) versus placebo over one year. Participants will undergo a neuropsychological exam using the NIH Toolbox Cognition Battery at both study enrollment and exit (after one year) to assess for changes\u002Fstability of cognition. Participants will receive monthly phone calls\u002Ftext messages to assess for adverse events and will be seen every three months for pill counts and routine laboratory monitoring. The primary outcome will be a comparison of adverse events across the two dosing strategies versus placebo. Early evidence for cognitive benefit will also be assessed from the results of the NIH Toolbox.",[639,104,34,106,105,140,640],"Sickle Cell Disease","Neuroinflammatory Response",[642,643,644,645],"sickle cell disease","benign hematology","cognitive dysfunction","neuroinflammation","2026-05-11",{"date":648,"type":57},"2026-05-14",{"date":650,"type":23},"2026-12-01",{"date":652,"type":23},"2028-06-15",{"name":90,"class":64},{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":658,"acronym":659,"eligibilityCriteria":660,"healthyVolunteers":18,"sex":19,"minAge":364,"maxAge":661,"enrollmentInfo":662,"targetDuration":4,"studyType":24,"phases":663,"briefSummary":664,"conditions":665,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":65},"100442999","effect-of-hypoxic-conditioning-on-cerebrovascular-health-in-the-elderly-100442999","NCT05048680","Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly","HYPOXAGE","Inclusion Criteria:\n\n* 60 to 80 years of age;\n* Being physically inactive (less than 150 min\u002Fweek of moderate to intense physical activity);\n* No chronic cardiovascular, respiratory, metabolic or neuromuscular disease counterindicating an exercise training or hypoxic conditioning program;\n* Health coverage;\n* Being able to provide written fully informed consent.\n\nExclusion Criteria:\n\n* Body-mass index \\>30 kg\u002Fm2;\n* Smoking (\\> cigarettes\u002Fday);\n* Alcohol use (\\> 10g\u002Fday);\n* Mental disorder or history of mental disorder;\n* Beta-blockade treatment;\n* Inability or refusal to provide informed consent;\n* No health coverage\n* People exceeding the annual ceiling of allowances received as a result of their participation in other clinical trials;\n* People deprived of freedom by judicial or administrative decision;\n* People subject to legal protection, who cannot be included in clinical trials.","80 Years",{"count":432,"type":23},[26],"In line with the ever-growing aging of Western populations, the development of preventive strategies to slow down the effects of aging on cardiovascular health represents a major challenge in order to preserve functional capacities and a sufficient quality of life in the elderly. The alteration of vascular function (at the cerebral and systemic level) with aging is an important feature in the clinical picture including a decrease in physical and cognitive capacities. Although physical activity is recognized as an essential means of combating the effects of aging, optimizing its effects by defining the most effective strategies of practice remains a key objective. Offering alternative interventions to exercise training is also necessary for people who are unwilling or unable to engage in a physical activity program. In this context, hypoxic conditioning, alone or in conjunction with rehabilitative exercise training, is a new therapeutic modality with strong preclinical validity, in particular from a cardiovascular standpoint, and used in other pathologies to improve cardiovascular function and exercise performance and quality of life. Our aim is, therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with exercise training) on cerebrovascular health in the elderly.",[666,667,668,669,215,34,670],"Hypoxia","Cerebral Hypoxia","Brain Diseases","Exercise","Healthy Aging","2026-05-04",{"date":673,"type":57},"2026-05-08",{"date":675,"type":57},"2021-10-13",{"date":677,"type":23},"2026-09",{"name":679,"class":64},"University Hospital, Grenoble",{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":684,"acronym":4,"eligibilityCriteria":685,"healthyVolunteers":12,"sex":316,"minAge":20,"maxAge":4,"enrollmentInfo":686,"targetDuration":4,"studyType":24,"phases":688,"briefSummary":690,"conditions":691,"keywords":697,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":702,"startDateStruct":704,"completionDateStruct":706,"leadSponsor":708,"locationsCount":65},"100572016","phase-2-memantine-and-exercise-to-improve-cognitive-function-and-modulate-biological-pathways-of-cognitive-decline-during-chemotherapy-in-breast-cancer-100572016","NCT06727773","Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer","Inclusion Criteria:\n\nIn order to participate in the study a subject must meet all of the eligibility criteria outlined below.\n\n* Female\n* Age ≥ 18 years at the time of consent.\n* Stage I-III Breast Cancer\n* Recommended chemotherapy\n* Enroll prior to 3rd cycle of chemotherapy\n* English-speaking\n\nExclusion Criteria:\n\n* Allergy to memantine\n* Previous chemotherapy (prior to the current regimen),\n* Severe cognitive impairment, defined by Blessed Orientation Memory Concentration Test Score ≥11\n* Myocardial infarction in the last 6 months\n* Cardiovascular or orthopedic limitations to exercise\n* Severe mental illness (i.e., schizophrenia or bipolar affective disorder)\n* Current alcohol or drug abuse\n* Inability to swallow capsules \\\u003C\u002F= 5mL\u002Fmin\n* CrCl \\\u003C\u002F= 5mL\u002Fmin",{"count":687,"type":23},90,[689],"PHASE2","This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \\& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.",[692,693,104,34,106,694,695,696],"Breast Cancer","Locally Advanced Breast Cancer","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III",[698,699,700,298,701],"chemotherapy","memantine","placebo-controlled","Get Real & Heel cancer exercise program",{"date":703,"type":57},"2026-05-06",{"date":705,"type":57},"2025-08-19",{"date":707,"type":23},"2029-06-15",{"name":709,"class":64},"UNC Lineberger Comprehensive Cancer Center",{"id":711,"slug":712,"hasResults":12,"nctId":713,"briefTitle":714,"officialTitle":715,"acronym":716,"eligibilityCriteria":717,"healthyVolunteers":18,"sex":19,"minAge":430,"maxAge":4,"enrollmentInfo":718,"targetDuration":4,"studyType":24,"phases":720,"briefSummary":721,"conditions":722,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":725,"startDateStruct":727,"completionDateStruct":729,"leadSponsor":731,"locationsCount":65},"100506654","a-smart-trial-of-adaptive-exercises-to-optimize-aerobic-fitness-responses-100506654","NCT05877196","A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses","Precision Medicine in Alzheimer's Disease: A SMART Trial of Adaptive Exercises and Their Mechanisms of Action Using AT(N) Biomarkers to Optimize Aerobic-Fitness Responses (The FIT-AD SMART Trial)","SMART","Inclusion Criteria:\n\nParticipants:\n\n* Clinical diagnosis of MCI or probable and possible mild AD dementia according to 2011 Alzheimer's association-NIA criteria.\n* Community-dwelling, e.g., homes and assisted living\n* Age 65 years and older\n* Medical clearance from PCP or cardiovascular provider\n* Have a qualified study partner\n* Agree to the blood draws\n* Verified MRI safety\n\nStudy Partner:\n\n* Age 18 or older\n* Contact with participant ≥ 2 times per week for ≥ 6 months\n* Know the participant's memory status and ability to perform activities of daily living\n* Consent to participant\n\nExclusion Criteria:\n\nParticipants\n\n* Resting HR ≤ 50 or ≥ 100 beats\u002Fmin after 5-minutes of quiet resting\n* American College of Sports Medicine contraindications to exercise\n* New, unevaluated symptoms or diseases a healthcare provider has not evaluated\n* Abnormal cardiac condition uncovered during VO2peak testing\n* Enrollment in another intervention that aims at improving cognition\n* Moderate to strenuous exercise ≥150 minutes a week in the previous 6 months\n* ≥ 2 anti-depression medications, or poorly managed or unstable depression\n* Poorly managed or unstable anxiety\n\nStudy partners:\n\n* none",{"count":719,"type":23},216,[26],"The goal of this clinical trial is to test 6 months of aerobic exercise in older adults who are 65 years or older and have mild cognitive impairment (MCI) or probable\u002Fpossible mild Alzheimer's Disease. The main questions it aims to answer are:\n\n* test the effects of aerobic exercise on aerobic fitness, white matter hyperintensity (WMH) volume, and patient-centered outcomes;\n* identify the best exercise to improve aerobic fitness and reduce non-responses over 6 months; and\n* examines the mechanisms of aerobic exercise's action on memory in older adults with early AD.\n\nParticipants will receive 6 months of supervised exercise, undergo cognitive data collection and exercise testing 5 times over a year span, have an MRI brain scan 3 times over a one-year span, and have monthly follow-up discussions on health and wellness.",[139,180,104,34,723,724],"Memory Loss","Memory Impairment",{"date":726,"type":57},"2026-05-05",{"date":728,"type":57},"2023-06-22",{"date":730,"type":23},"2028-06-30",{"name":732,"class":64},"Arizona State University",{"id":734,"slug":735,"hasResults":12,"nctId":736,"briefTitle":737,"officialTitle":738,"acronym":739,"eligibilityCriteria":740,"healthyVolunteers":12,"sex":19,"minAge":430,"maxAge":741,"enrollmentInfo":742,"targetDuration":4,"studyType":24,"phases":743,"briefSummary":744,"conditions":745,"keywords":748,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":754,"lastUpdatePostDateStruct":755,"startDateStruct":756,"completionDateStruct":758,"leadSponsor":760,"locationsCount":65},"100484793","in-dementia-clinical-trials-100484793","NCT05592678","δ in Dementia Clinical Trials","Novel Methods for Clinical Trials in Dementia and Cognitive Decline","δND","Inclusion Criteria:\n\n1. Ambulatory outpatient volunteers with co-informants.\n2. Aged 65-100 years\n3. Clinical diagnosis of AD, or MCI.\n4. Capacity to give informed consent.\n5. GDS score (15 item) ≤ 8.\n6. No significant visual or hearing impairments\n7. Standardized dECog score between 1.0 and 5.0 relative to ADNI's cohort.\n\nExclusion Criteria:\n\n1. A history of psychosis, including visual hallucinations;\n2. History or treatment for Parkinson's, or tremor, or Rapid Eye Movement (REM) behavior disorder;\n3. History of bradycardia or syncopal events;\n4. Treatment for cancer in the last 5 years (excluding skin cancers);\n5. Major surgery in the last year;\n6. Treatment for a seizure disorder with anticonvulsants;\n7. Treatment for agitation or psychosis with neuroleptics (treatment of anxiety or insomnia allowed);\n8. Current treatment with donepezil or any other AChEI or exposure within the last six months\n9. With a recently started Donepezil Rx (\\\u003C 2 weeks), inability to stop Donepezil treatment for 14 days prior to study enrollment.\n10. AChEI treatment not appropriate due to negative risk\u002Fbenefit ratio based on medical Hx and symptoms during screening. Evaluated by PI and referring clinician.\n11. Co-participation in another study that the PI feels would pose a safety risk or adversely affect data integrity of this study.","100 Years",{"count":172,"type":23},[26],"The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are:\n\n* Can an intervention's outcome be better assessed by a latent variable (\"δ\") integrating cognitive performance with functional status?\n* Can latent biomarkers of δ guide the selection of an intervention that will modulate dementia severity?\n* Can a latent variable, derived from information collected remotely from caregivers, preselect subjects most likely to respond to the intervention?\n* Is the effect of the intervention in fact medicated by changes in the targeted biomarker?\n\nIn this case, the biomarker will be a latent variable derived from several proteins measured in blood (i.e., so-called \"adipokines\"). The intervention will be donepezil, a medication approved for the treatment of Alzheimer's Disease, but only recently associated with adipokine changes.\n\nParticipants with cognitive impairment and their caregivers will be interviewed by telephone and those newly prescribed donepezil by their provider for cognitive impairment will be recruited and enrolled. On the basis of the caregiver's report, the cognitively impaired subjects will be assigned to two groups based on a prediction of their response to donepezil. Researchers will compare those groups to see if dementia severity, as measured by δ, improves in predicted responders, and whether the change in the d-score is mediated by changes in adipokines.",[746,32,34,747],"Alzheimer's Disease (AD)","Mild Cognitivie Impairment (MCI)",[749,750,751,752,753],"adipokines","cognition","dementia","functional status","intelligence","2026-04-30",{"date":726,"type":57},{"date":757,"type":57},"2024-08-05",{"date":759,"type":23},"2028-11-30",{"name":761,"class":64},"The University of Texas Health Science Center at San Antonio",{"id":763,"slug":764,"hasResults":12,"nctId":765,"briefTitle":766,"officialTitle":767,"acronym":4,"eligibilityCriteria":768,"healthyVolunteers":12,"sex":19,"minAge":131,"maxAge":4,"enrollmentInfo":769,"targetDuration":4,"studyType":24,"phases":770,"briefSummary":771,"conditions":772,"keywords":774,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":780,"lastUpdatePostDateStruct":781,"startDateStruct":782,"completionDateStruct":784,"leadSponsor":786,"locationsCount":788},"100516315","mindwalk-intervention-for-older-south-asian-caregivers-of-people-with-cognitive-disabilities-cd-100516315","NCT06002919","MindWalk Intervention for Older South Asian Caregivers of People With Cognitive Disabilities (CD)","MindWalk: A Mindful Walking Intervention for Older South Asian Family Caregivers of People With Cognitive Disabilities (CD) With Perceived Psychological Stress","Inclusion Criteria:\n\n* Older South Asian family caregivers (45 years or older) caring for a person with cognitive disability of any age\n* Self-reported insufficient physical activity (defined as participating in moderate physical activity less than 60 min\u002Fweek) and not engaged in mindfulness training\n* Self-reporting of experiencing psychological stress;\n* Own a smartphone with a data plan or Bluetooth-enabled device (e.g., tablets such as iPad) to sync data from the Fitbit tracker to the Fitbit app and to receive text messages\n* Ability to speak, understand, read and write English; ability to provide informed consent\n\nExclusion Criteria:\n\n* Non-South Asian caregivers\n* Caregivers less than 45 years old\n* Having self-reported sufficient physical activity (defined as participating in moderate physical activity more than 60 min\u002Fweek) and engaged in some form of mindfulness training\n* Not owning a smartphone with a data plan or Bluetooth-enabled device (e.g., tablets such as iPad)\n* Mobility limitation\n* Taking medications or other behavioral treatment for stress reduction; acute or chronic diseases at baseline\n* Inability to understand, speak, read, and write English\n* Inability to provide informed consent",{"count":564,"type":23},[26],"Older South Asian family caregivers experience elevated psychological stress and limited physical activity (PA) due to caregiving responsibilities and additional factors such as lack of access to services, cultural\u002Flinguistic barriers, stigma and discrimination. South Asian family caregivers are especially underserved and are a growing ethnic group in the US. Both PA and cognitive training (CT) have shown to improve cognitive function in older adults who experience cognitive function decline because of psychological stress. However, there are no studies using this approach for this population. We propose a randomized control trial pilot study to address this gap. Driven by a Community Advisory Committee (CAC) we will develop this 12-week mindful walking intervention using a participatory methodology in partnership with UIC's Cognition Behavior and Mindfulness Clinic that combines the PA of walking and the CT through mindfulness. We will recruit fifty participants and will randomly and equally assign 25 people to the intervention and 25 people to the control group. The intervention will include: 1) a mindful walking training followed by 2) a prescribed mindful walking regimen, 3) self-reporting of adherence to regimen by the participants using activity logbooks and use of a user-friendly PA tracker (Fitbit) for daily step count, and 4) personalized text messages with reminders and motivational messages for participants to do the mindful walking as prescribed including a weekly check-in call or text message for accountability. The primary aim of the proposed pilot study is to evaluate the feasibility and acceptability of the protocol and intervention implementation. A secondary aim will evaluate the intervention to examine preliminary efficacy in reduction of psychological stress, improvement in cognitive function, increase in physical activity, and increased self-efficacy (self-efficacy for coping with stress, self-efficacy for physical activity, and overall self-efficacy). The findings of this pilot project will provide evidence-based data to support a larger scale study proposal for future funding such as the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) field initiative award, or the National Institute of Health (NIH) Research Project Grant (R21 NIH Exploratory\u002FDevelopmental Research Grant Award) award, especially National Institute on Aging (NIA) grants.",[773,34],"Stress, Psychological",[775,776,777,778,45,779],"Caregiver of a person with cognitive disability","Perceived psychological stress","Cognitive Function","Mindful Walking","Self-efficacy","2026-04-27",{"date":621,"type":57},{"date":783,"type":57},"2023-10-31",{"date":785,"type":23},"2026-12-31",{"name":787,"class":64},"University of Illinois at Chicago",8]